Daiichi Sankyo's Majority Stake In Ranbaxy Will Increase Production Capacity In India, Expand Global Footprint In Developing Markets – Japanese Analysts
This article was originally published in PharmAsia News
Executive Summary
TOKYO - Daiichi Sankyo will make a foray into the generics business with its Ranbaxy acquisition, and will shift much of its domestic production to Ranbaxy to save costs, analysts in Japan said. However, the Japanese company will not sell its brand drugs through Ranbaxy's distribution channels, nor will the two companies start a joint generics business in Japan, they speculated
You may also be interested in...
Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps
TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman
Daiichi Sankyo To Expand European Presence With Acquisition Of 130 Merck KGaA Medical Reps
TOKYO - Daiichi Sankyo's German subsidiary reached an agreement to acquire approximately 130 primary-care medical representatives now working for Merck Serono in Germany as part of the Japanese company's European business expansion, a Daiichi Sangyo spokesman
Japan’s Daiichi Sankyo In “Transformational” Deal to Buy Majority Stake In India’s Ranbaxy Labs
NEW DELHI - Japan's Daiichi Sankyo will buy a majority stake in India's top drug maker in a deal that will vault the combined operations into the top 15 pharmaceutical firms globally and end the founding Singh family's role as largest shareholder of Ranbaxy Laboratories